O’Dwyer, Peter J. http://orcid.org/0000-0002-9302-4073
Gray, Robert J.
Flaherty, Keith T. http://orcid.org/0000-0002-3402-0478
Chen, Alice P. http://orcid.org/0000-0002-1426-853X
Li, Shuli
Wang, Victoria
McShane, Lisa M. http://orcid.org/0000-0001-8195-3206
Patton, David R.
Tricoli, James V.
Williams, P. Mickey http://orcid.org/0000-0002-3309-5988
Iafrate, A. John
Sklar, Jeffrey
Mitchell, Edith P.
Takebe, Naoko
Sims, David J.
Coffey, Brent
Fu, Tony
Routbort, Mark
Rubinstein, Larry V. http://orcid.org/0000-0002-9720-9737
Little, Richard F. http://orcid.org/0000-0002-4091-1699
Arteaga, Carlos L. http://orcid.org/0000-0003-0870-9586
Marinucci, Donna
Hamilton, Stanley R.
Conley, Barbara A.
Harris, Lyndsay N. http://orcid.org/0000-0002-9774-6719
Doroshow, James H.
Article History
Received: 23 January 2023
Accepted: 28 April 2023
First Online: 15 June 2023
Competing interests
: P.J.O.’D. received research support from Pfizer, Genentech, BMS, AstraZeneca, GSK, Five Prime, FortySeven, Merck, Syndax, BBI, Novartis, Celgene, Incyte, Lilly/Imclone, array, h3biomedicine, Taiho, Minneamrata, pharmacyclics/abbvie and Mirati; and provided expert testimony for Dai-ichi Sankyo. K.T.F. has served on the board of directors of Loxo Oncology, Clovis Oncology, Strata Oncology, Checkmate Pharmaceuticals, Kinnate Pharmaceuticals and Scorpion Therapeutics; on the scientific advisory boards of PIC Therapeutics, Apricity, Oncoceutics, Fog Pharma, Tvardi, xCures, Monopteros, Vibliome, ALX Oncology, OMRx, Soley Therapeutics and Quanta Therapeutics; as a consultant to Lilly, Novartis, Genentech and Takeda; and received research funding from Novartis and Sanofi. A.J.I. holds stock options in, and has served on the scientific advisory boards of, PAIGE.AI, Kinnate Biopharma, Repare Therapeutics and SequreDx, and has received research support from Invitae. C.A. serves or has served as a scientific advisor to Novartis, Lilly, Merck, AstraZeneca, Daiichi Sankyo, Sanofi, TAIHO Oncology, PUMA Biotechnology, OrigiMed, Arvinas and the Komen Foundation; received grant support from Pfizer, Lilly and Takeda; and holds minor stock options in Provista Diagnostics. The remaining authors report no competing interests.